An observational study in Myofascial Pain Syndrome - Neck, Spondyloarthrosis and Neck Pain, sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Spondylarthritis with a site in Poland — 2 open to participants now, 2 under way, none of them phase 3. Spondylarthritis · Poland.
Among the 12 studies in Spondylarthritis with a site in Poland, this one is the only one that started in 2025, is one of 3 observational ones, and was the 12th registered.
203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.
Browse Spondylarthritis studies →2 of the 12 studies in Spondylarthritis with a site in Poland are open now. Recruiting first, the newest first:
University of Siena · Sites in Poland, Algeria, Australia and 19 more countries
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 240 across 93 observational studies indexed under Spondylarthritis.
Median enrollment 383 across the 9 interventional studies, 708 across the 3 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 9 most frequent:
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland is the lead sponsor of 10 studies on the registry; 7 are open to participants now.
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland has 1 study filed under Spondylarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Spondylarthritis with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to assess the concentration of anti-inflammatory markers after the use of cervical spine mesotherapy in the course of pain syndrome. The study is randomized. Patients will be divided into two groups: A - mesotherapy using injectable type I collagen, B - mesotherapy using 1% lignocaine. The mesotherapy procedure will be performed five times, at weekly intervals. Blood will be collected before the start of mesotherapy, a week after its completion and after 3 months of follow-up. In addition, the effectiveness and safety of mesotherapy of the cervical spine will be assessed.
Study aim:
The main objective of this article was to answer the question: Can biomarkers of inflammatory processes in the blood and BDNF be used to evaluate the effectiveness of collagen mesotherapy in chronic CMPS? The second objective of this article is to evaluate the safety of collagen mesotherapy in chronic CMPS.
Material and methods:
The study was conducted on patients aged 18 to 80 years, of both sexes, with local, chronic cervical spine pain syndrome, without radiation of symptoms to the upper limb. The study subjects were recruited at the National Institute of Geriatric, Rheumatology and Rehabilitation in Warsaw. Patients will be recruited according to the inclusion and exclusion criteria. The study is randomized. Patients will be divided into two groups: A - mesotherapy using injectable type I collagen, B - mesotherapy using 1% lignocaine.
Each patient will have blood collected before starting mesotherapy (on the same day) to determine anti-inflammatory markers (TNF-alpha, interleukin-1-beta, interleukin-6) and BDNF. Again, a week after the end of mesotherapy (five treatments) and after 6-week of follow-up, blood will be collected to determine the same markers.
In addition, the effectiveness and safety of mesotherapy of the cervical spine will be assessed. A Numeric Rating Scale (VAS) and the Neck Disability Index (NDI) scale will be used.
Patients with chronic cervical spine pain, of a muscular, myofascial and overload nature, will be qualified for the study and undergo spinal mesotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concentration of anti-inflammatory markers
Blood collection before starting the mesotherapy treatment (on the same day), one week after its completion, and after 6 weeks follow-up
Time frame: Blood collection before starting the mesotherapy treatment (on the same day), one week after its completion (after 5 weeks from start), and after 6 weeks from end
Plan to share: No
Ran from Jan 2025 to primary completion in Sep 2025, 8 months.
Of 51 observational studies under Spondylarthritis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 201. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland